International Rett Syndrome Foundation Translational Research Program
Cycle 2 Letter of Intent due: July 1, 2013
IRSF announces the availability of HeART (Help Accelerate RTT Therapeutics) and ANGEL (Advanced Neurotherapeutic Grant of Excellence) grant awards to promote the development and testing of therapeutics to treat and reverse Rett syndrome (RTT) and its symptoms. These award mechanisms seek to facilitate the development and testing of novel therapeutics targeting the underlying pathology of the disorder, thereby leading to an amelioration of symptoms or ultimately a pharmacological reversal of RTT. Through these awards, IRSF seeks to foster academic and public-private partnerships and further facilitate drug discovery, development and testing.
IRSF encourages novel research programs that broadly encompass the following areas of unmet need:
Design, synthesis and testing of potential disease modifying therapeutics to treat or reverse RTT
Testing of existing therapeutics both in vitro and in vivo to repurpose their use in RTT
Development and/or validation of in vitro and in vivo models of RTT for therapeutic testing
Development and/or validation of novel biomarkers for objective clinical trials outcome measures
Testing of IND-ready therapeutics in pilot clinical trials
IRSF encourages investigators to utilize the newly available IRSF SMART Library of compounds in their proposed studies.
HeART (Help Accelerate RTT Therapeutics) Grant Award
Goal: To provide seed funding for early stage drug discovery and development efforts.
Funding: The maximum funding level for HeART grant awards is $150,000 for two years.
HeART grant awards are provided for cell-based assay development, early-stage drug discovery and development, early stage medicinal chemistry efforts on high value candidate therapeutics, cell-based screening of candidate therapeutics and follow-on early-stage in vivo testing. Grant applications for exploratory studies towards development of biomarkers or objective clinical outcome measures will also be considered.
ANGEL (Advanced Neurotherapeutic Grant of Excellence) Grant Award
Goal: To provide funding for the later stages of translational research.
Funding: The maximum funding level for ANGEL grant awards is $300,000 per year for up to two years.
Proposals must be comprised of very specific programs focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates. This mechanism requires development of a milestone based research plan, interim reporting on milestones and interaction with IRSF staff prior to and during the award period. The budget and duration of funding are variable and continued funding will be based on satisfactory progress on milestones. Applications are usually solicited, however, unsolicited proposals will be considered. Preliminary inquiries are required to determine IRSF’s level of interest prior to submission of an Expression of Interest (EOI).
Awards will be made in two cycles in 2013.
Please Note: IRSF requires all applicants to use our online submission process.
For application submission inquiries, please contact:
Janice Ascano, Ph.D. Manager of Grants and Research - firstname.lastname@example.org | 917-267-4504
For program related inquiries, please contact:
Steve Kaminsky, Ph.D., Chief Science Officer - email@example.com | 301-961-1559